7Baggers
 Ironwood seals the deal on VectivBio merger  Pharmaceutical Technology Wed, 13 Dec 2023 08:00:00 GMT
 Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio  Business Wire Tue, 12 Dec 2023 08:00:00 GMT
 ironwood pharmaceuticals presents positive final data from stars ...  Business Wire Mon, 16 Oct 2023 07:00:00 GMT
 alert: the m&a class action firm continues investigating the ...  PR Newswire Sat, 17 Jun 2023 07:00:00 GMT
 VectivBio taken over in $1bn acquisition  European Biotechnology Magazine Wed, 24 May 2023 07:00:00 GMT
 these small-cap biotech stocks have the wind at their back  RealMoney Wed, 24 May 2023 07:00:00 GMT
 Ironwood acquires VectivBio in $1B deal  Labiotech.eu Tue, 23 May 2023 07:00:00 GMT
 ironwood to buy swiss biotech for $1 billion  The Boston Globe Mon, 22 May 2023 07:00:00 GMT
 saudi arabia changes tack with pop stars and pop art  Bloomberg Mon, 22 May 2023 07:00:00 GMT
 did these 6 biotech stocks catch your eye?  RTTNews Fri, 14 Oct 2022 07:00:00 GMT
 advises vectivbio underwritten offering ordinary shares  Latham & Watkins LLP - Thu, 13 Oct 2022 07:00:00 GMT
 vectivbio announces pricing of $125 million underwritten offering ...  GlobeNewswire Thu, 13 Oct 2022 07:00:00 GMT
 vectivbio announces pricing of $30 million public offering of ordinary shares  Marketscreener.com Tue, 14 Jun 2022 07:00:00 GMT
 vectivbio to acquire comet therapeutics and host r&d day  GlobeNewswire Tue, 31 Aug 2021 07:00:00 GMT
 vect vectivbio holding ag  Quantisnow Mon, 30 Aug 2021 11:04:29 GMT
 irwd ironwood pharmaceuticals inc.  Quantisnow Wed, 28 Jul 2021 01:29:25 GMT
 vectivbio announces pricing of initial public offering  GlobeNewswire Thu, 08 Apr 2021 07:00:00 GMT
 harmony biosciences appoints sandip kapadia as chief financial ...  PR Newswire Mon, 15 Mar 2021 07:00:00 GMT
 therachon expands rare disease pipeline with acquisition of ...  PR Newswire Tue, 09 Oct 2018 07:00:00 GMT

VectivBio Holding AG Ordinary Shares
(NASDAQ:VECT) 

VECT stock logo

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the tre...

Sector: Healthcare
Industry: Biotechnology

Share this website to your friends